The Schedule III Trade: Is MSOS Finally Ready—or Is Washington Setting Another Trap?

Cannabis investors have heard this story before.

A president makes a statement. Federal agencies begin a review. Marijuana stocks explode higher. Politicians promise that reform is finally coming.

Then nothing happens.

The rally fades, deadlines slip, momentum traders leave and long-term shareholders are trapped holding another 40% decline.

That cycle has repeated so many times that skepticism is no longer bearishness. It is rational.

Yet the Schedule III story entering the second half of 2026 is different in one important respect: the federal government has finally moved beyond speeches and recommendations.

In April, the Justice Department and Drug Enforcement Administration placed FDA-approved marijuana products and marijuana sold through state-regulated medical programs into Schedule III. The government simultaneously began an expedited process to consider moving marijuana more broadly—including the adult-use market—from Schedule I to Schedule III. The Justice Department confirmed the medical action and broader review.

The broader DEA hearing ran from June 29 through July 15. Participants can submit transcript corrections through August 17, after which the administrative process moves toward post-hearing briefs, a recommended decision and ultimately a final agency order. The DEA’s latest procedural order confirms that the hearing is complete.

That is genuine progress.

It is still not the same thing as a completed Schedule III catalyst for the entire industry.

For investors considering the AdvisorShares Pure US Cannabis ETF, better known as MSOS, or its daily leveraged counterpart MSOX, that distinction is everything.

How we got here

The modern rescheduling process began in October 2022, when President Biden asked the Department of Health and Human Services and the attorney general to review marijuana’s federal classification.

HHS recommended Schedule III in August 2023.

The Justice Department published a proposed rule in May 2024.

An administrative hearing was announced, delayed and buried under procedural disputes. President Trump revived the process with a December 2025 executive order directing the attorney general to expedite rescheduling. The government then finalized the narrower medical-marijuana action in April 2026 and created a new hearing process for marijuana as a whole.

The timeline tells investors two things simultaneously:

1. The federal government has traveled much further than it had during earlier cannabis rallies.
2. Even an “expedited” federal process can consume months or years.

The market has therefore stopped assigning much value to promises.

Investors want a final order, an effective date and clear tax guidance. Until those arrive, every political headline will remain vulnerable to another sell-the-news reaction.

What Schedule III actually changes

The most important benefit is not symbolic recognition or easier research.

It is taxes.

Section 280E of the Internal Revenue Code prevents businesses trafficking in Schedule I or Schedule II substances from deducting ordinary operating expenses. Cannabis operators may deduct cost of goods sold, but expenses such as payroll, rent, advertising and many administrative costs can be disallowed.

That forces state-legal cannabis companies to pay federal taxes on something closer to gross profit than ordinary corporate profit.

The result can be an enormous effective tax rate even when the underlying business produces little net income or free cash flow.

The IRS explicitly states that Section 280E applies to businesses selling marijuana because marijuana has historically been classified in Schedule I. The statute applies only to substances in Schedule I or II. The IRS Taxpayer Advocate explains the restriction.

Moving qualifying operations to Schedule III removes them from the language of 280E.

That can create several immediate financial benefits:

• Lower federal tax expense
• Higher operating cash flow
• Improved ability to service debt
• More capital for store openings and acquisitions
• Lower risk of distressed asset sales
• Better earnings visibility
• Potentially higher equity valuations

This is not an imaginary accounting benefit.

Green Thumb Industries reported $102 million of federal and state income-tax expense during the first nine months of 2025 despite generating approximately $135 million of income before taxes. It paid about $22 million in cash taxes over the same period. Green Thumb’s SEC filing details the disparity.

Trulieve’s 2025 filing disclosed substantial accrued interest connected to its Section 280E tax position, illustrating how the issue can compound across multiple years. Trulieve’s annual filing reported $65.8 million of accrued interest related to that position at year-end.

Eliminating 280E broadly would not create new customers overnight. It would allow existing revenue to produce substantially more distributable cash.

That is the heart of the MSOS bull case.

What Schedule III does not change

Rescheduling is not federal legalization.

It does not automatically:

• Permit recreational marijuana nationwide
• Authorize unrestricted interstate commerce
• Replace state licensing systems
• Guarantee access to every bank or credit-card network
• Allow every cannabis company to list on Nasdaq or the NYSE
• Erase past tax liabilities
• Resolve every conflict between state and federal law
• Prevent lawsuits challenging the final rule

Cannabis would remain a controlled substance, and companies would continue operating inside a complicated combination of federal regulation and individual state programs.

Exchange access may improve, especially as companies reorganize qualifying medical operations. Institutional custody could also become easier.

Neither is guaranteed merely because the words “Schedule III” appear in the Federal Register.

This is why the industry can receive meaningful tax relief without immediately becoming a normal consumer-products sector.

MSOS is more concentrated than it looks

MSOS is often described as a diversified cannabis ETF. Technically, it owns exposure to multiple companies. Economically, it is heavily concentrated in a handful of major U.S. operators.

As of July 21, its four largest positions were:

Holding	MSOS weight
Curaleaf	28.79%
Trulieve	26.91%
Green Thumb Industries	18.79%
Glass House Brands	8.77%

Those four positions represented approximately 83% of the fund. AdvisorShares publishes the holdings daily.

That concentration has advantages.

Curaleaf, Trulieve and Green Thumb are among the largest operators positioned to capture substantial tax savings. If broader Schedule III treatment improves their cash flow, MSOS should respond quickly.

It also creates risk.

Company-specific tax disputes, debt problems, state exposure or operational disappointments can overwhelm gains elsewhere in the portfolio. MSOS is a sector vehicle, but it should not be treated like a broad-market index fund.

Its net expense ratio is 0.78%, and some holdings are obtained through total-return swaps because federal restrictions have historically complicated direct ownership and exchange listing.

At approximately $4.46, MSOS remains far below the levels reached during earlier cannabis manias. Its 52-week range is roughly $2.68 to $7.25.

The depressed price reflects both opportunity and a market that no longer trusts Washington.

Why MSOX is a completely different trade

MSOX seeks approximately twice the daily return of MSOS before fees and expenses.

The word “daily” is critical.

MSOX does not promise twice the return of MSOS over a month, a year or the duration of the rescheduling process. It resets its leverage every trading day through derivatives and swap agreements.

AdvisorShares explicitly warns that returns over periods longer than one day can differ substantially from twice MSOS’s performance, particularly because cannabis stocks are highly volatile. The MSOX fund disclosure states that it is intended for investors who actively monitor their positions.

Consider a simplified example.

If MSOS falls 20% on one day and then rises 25% the next day, it returns to its starting value:

• $100 falls to $80
• $80 rises 25% to $100

A theoretical 2x daily product would fall 40% and then rise 50%:

• $100 falls to $60
• $60 rises 50% to $90

MSOS finishes flat. The leveraged product loses 10%.

That is volatility decay.

MSOX can perform spectacularly when MSOS moves rapidly and consistently in one direction. It can also lose value while MSOS goes sideways through a violent sequence of rallies and selloffs.

Its net expense ratio is 0.97%, but daily compounding and financing costs matter considerably more than the published management fee.

MSOX is not simply “MSOS with more upside.” It is a short-duration trading instrument that requires correct direction, timing and path.

The catalysts that could finally move the sector

1. The post-hearing process

The broad Schedule III hearing is finished. Transcript corrections are due by August 17, and the docket must then move through post-hearing submissions and the administrative decision process.

The next major catalyst is not another politician saying reform is important. It is a favorable written decision that materially advances the rule toward completion.

2. A final order covering adult-use marijuana

The April action addressed FDA-approved products and state-regulated medical marijuana. A broader final order would dramatically expand the tax and valuation implications across adult-use operations.

This is the catalyst capable of changing the market’s earnings models—not merely producing another temporary headline rally.

3. IRS and Treasury guidance

Even after broader rescheduling, companies and investors will need clarity regarding:

• The effective date of 280E relief
• Treatment of a partial tax year
• Whether past returns may be amended
• Allocation between medical and adult-use operations
• Inventory-accounting transitions
• Existing tax disputes and accrued interest

A favorable rule without clear implementation guidance could still create months of uncertainty.

4. Cannabis earnings

The best operators must prove that tax savings become free cash flow rather than disappearing into price competition, expansion spending or executive compensation.

Investors should watch:

• Cash taxes paid
• Operating cash flow
• Net debt
• Interest expense
• Wholesale pricing
• Same-store sales
• Capital expenditures
• Share issuance

Schedule III can improve a strong business. It cannot make a weak operator disciplined.

5. Exchange and custody access

Additional U.S. listings or clearer institutional-custody rules could expand the buyer base. Cannabis equities have historically traded with limited institutional sponsorship because leading operators were confined to Canadian exchanges and U.S. over-the-counter markets.

A larger pool of investors could raise both liquidity and valuation multiples.

6. Banking legislation

Schedule III does not make comprehensive banking reform irrelevant. Legislation protecting financial institutions that serve state-legal cannabis companies could improve payment processing, lending access and security.

Congress has repeatedly approached banking reform without finishing it. Until a bill becomes law, investors should assign it limited value.

7. State-level expansion

New adult-use launches, ballot measures and medical-market growth can still move individual operators even if Washington stalls.

For MSOS, state catalysts matter most when they benefit Curaleaf, Trulieve and Green Thumb because those companies dominate the portfolio.

How much upside could MSOS have?

No one can responsibly produce a precise price target for an ETF driven by an unfinished federal rule. Scenario analysis is more useful.

With MSOS near $4.46, the following are analytical ranges rather than formal targets:

Scenario	Possible MSOS reaction	Thesis
Process stalls again	$2.75–$3.75	Reform premium disappears and the ETF revisits the lower end of its range
Medical relief remains, broader rule delayed	$4.00–$5.50	Tax benefits help some operations, but adult-use uncertainty caps the multiple
Favorable broad Schedule III order	$6.50–$8.00	MSOS retests or exceeds its 52-week high as cash-flow estimates rise
Schedule III plus tax clarity and institutional access	$8.00–$10.00+	Tax relief combines with multiple expansion and new investor demand

Reclaiming the 52-week high of $7.25 would represent approximately 63% upside from $4.46.

A return to $9 would roughly double the ETF.

Those outcomes are plausible if broader rescheduling is completed. They are not guaranteed, and the downside scenario remains substantial if the process is delayed, narrowed or defeated in court.

The cleaner way to structure the trade

Strategy 1: MSOS as the core position

For investors who believe broader Schedule III treatment will eventually arrive but cannot predict the exact week, MSOS is the more appropriate vehicle.

A staggered approach can reduce headline risk:

• Establish one-third of the intended position at current levels
• Reserve one-third for a meaningful market or sector pullback
• Add the final third only after a favorable administrative or final decision

This structure accepts that the first purchase may not mark the bottom. It also prevents the investor from being completely absent if the decisive order arrives unexpectedly.

The defining advantage is time. MSOS can be held through delays without the daily leverage reset embedded in MSOX.

Strategy 2: A core-and-catalyst combination

A more aggressive structure could place 80% to 90% of the cannabis allocation in MSOS and reserve 10% to 20% for MSOX around a specific, dated catalyst.

That could include:

• A major DEA docket decision
• Publication of a final rule
• Treasury or IRS implementation guidance
• A significant exchange-listing announcement

MSOX would then be reduced or closed within days rather than held indefinitely.

This preserves long-term exposure through MSOS while using leverage only when the probability of an immediate directional move is unusually high.

Strategy 3: Defined-risk MSOS options

Investors comfortable with options could use an MSOS bull call spread several months beyond the anticipated regulatory window.

The general structure would be:

• Buy an at-the-money or slightly in-the-money call
• Sell a call approximately 30% to 50% above the current ETF price
• Limit the debit to an amount that can be lost entirely

The short call helps offset the elevated implied volatility that often appears before federal cannabis catalysts.

The danger is still timing. Washington can remain unfinished longer than an option remains alive.

Strategy 4: MSOX as a pure momentum trade

MSOX is appropriate only when the investor has:

• A specific catalyst
• A short intended holding period
• A predefined loss limit
• A profit-taking plan
• The ability to monitor the position daily

At approximately $2.51, the low share price can make MSOX look harmless. It is not.

If MSOS falls 15% during a violent disappointment, MSOX could lose approximately 30% in a single session before compounding effects and market dislocations. Multiple bad sessions can devastate the position.

The correct position size should therefore be based on dollar risk—not on how inexpensive each share appears.

What would invalidate the bullish thesis?

The Schedule III trade becomes materially weaker if:

• The administrative decision rejects broader rescheduling
• The final order excludes a significant portion of adult-use operations
• Courts stay or overturn the rule
• IRS guidance limits the expected 280E benefit
• Major operators fail to convert tax relief into cash
• Debt and interest expense absorb the savings
• State-level pricing continues deteriorating
• MSOS breaks toward its 52-week low despite favorable federal developments

A final rule could also produce a sell-the-news event after an initial spike.

Investors who have waited years may use the catalyst to exit. Companies could issue stock into stronger prices. The market may quickly shift from valuing political hope to scrutinizing revenue growth and balance sheets.

Schedule III would change the financial structure of the industry. It would not eliminate competition or guarantee good capital allocation.

The bottom line

The cannabis trade is no longer based entirely on promises.

Medical marijuana has received meaningful Schedule III treatment, the broader DEA hearing has concluded and the federal process is further advanced than it was during previous MSOS rallies.

But the industry still does not have everything investors have been waiting for.

Adult-use treatment remains unresolved. Tax implementation requires clarity. Banking reform remains incomplete. Litigation risk is real. The final timeline still belongs to Washington.

That makes MSOS the more defensible vehicle for investors willing to wait and MSOX the more dangerous—but potentially explosive—instrument for trading a specific catalyst.

MSOS offers time.

MSOX demands timing.

After years of political promises and disappearing rallies, that may be the most important distinction in the entire cannabis market.